← Leaderboards
Gayane Yenokyan
Duke University
$3,553,064
Attributed
$10,198,688
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2021–25$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,198,688 · 3
By mechanism
U24$10,198,688 · 3
Top collaborators
- Daniel F Hanley5 shared
- Hrishikesh Chakraborty4 shared
- Richard Thompson4 shared
- Kanecia Obie Zimmerman4 shared
Most similar at Duke University
Same institution · by research overlap
- Daniel B Mark$29,174,449
- Lori A. Setton$15,853,009
- Harald Moller$135,503
- Amy M Pastva$3,249,097
- Hrishikesh Chakraborty$16,373,642
Others in their field
Other Emerging Leaders on “Safety”
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
- Kimberly Smith · Ppd Development Lp$122,008,792
- Klaus Romero · Critical Path Institute$90,404,592
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$75,904,237
- Yunda Huang · Fred Hutchinson Cancer Center$70,809,823
- Leonard Freedman · Leidos Biomedical Research, Inc.$64,938,611
Research focus
SafetyDesignClinical TrialsEvidence BaseQuality Of LifeEvaluationRandomizedOralMortalityMonitorEfficacy EvaluationCaringStandard Of CareTreatment StrategyParticipantPreparationInnovationOperationPrimary EndpointEnsureEventCessation Of LifeCollaborationsCommunication
Grant awards (9)
2/2 REACT-AF: Rhythm Evaluation for AntiCoagulaTion with Continuous Monitoring of Atrial Fibrillation$1,462,441
U24 · FY2025 · HL
ASTRO: Adjuvant STeroid Outcomes in idiopathic subglottic stenosis: A randomized trial$921,009
U24 · FY2025 · HL
2/2 Kids MoD PAH Trial: Mono- vs. Duo-Therapy for Pediatric Pulmonary Arterial Hypertension-DCC$562,043
U24 · FY2025 · HL
2/2 REACT-AF: Rhythm Evaluation for AntiCoagulaTion with Continuous Monitoring of Atrial Fibrillation$1,450,909
U24 · FY2024 · HL
2/2 Kids MoD PAH Trial: Mono- vs. Duo-Therapy for Pediatric Pulmonary Arterial Hypertension-DCC$819,482
U24 · FY2024 · HL
2/2 REACT-AF: Rhythm Evaluation for AntiCoagulaTion with Continuous Monitoring of Atrial Fibrillation$1,289,729
U24 · FY2023 · HL
2/2 Kids MoD PAH Trial: Mono- vs. Duo-Therapy for Pediatric Pulmonary Arterial Hypertension-DCC$917,737
U24 · FY2023 · HL
2/2 REACT-AF: Rhythm Evaluation for AntiCoagulaTion with Continuous Monitoring of Atrial Fibrillation$1,839,921
U24 · FY2022 · HL
2/2 Kids MoD PAH Trial: Mono- vs. Duo-Therapy for Pediatric Pulmonary Arterial Hypertension-DCC$935,417
U24 · FY2021 · HL